Clinical Trial Update: Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating iptacopan (LNP023) in adults with atypical hemolytic uremic syndrome who are naive to complement inhibitors; the study is currently a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Hemolytic Uremic Syndrome

Drugs mentioned

• iptacopan (LNP023) (iptacopan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Atypical Hemolytic Uremic Syndrome | Phase 3 | Status: ACTIVE_NOT_RECRUITING